Condition: Breast Cancer · Sponsor: The First Affiliated Hospital with Nanjing Medical University
Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer
This description comes directly from the study's public registry record.
Yongmei Yin, Ph.D · 025-68307102 · ymyin@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| Jiangsu Provincial People's Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06254690